Article Text

Download PDFPDF

4CPS-106 AUC-survival reanalysis of TROPiCS-02 trial with sacituzumab govitecanfor metastatic luminal breast cancer
  1. JI Bretones Pedrinaci1,
  2. CM Dominguez Santana2,
  3. N Jimenez Carbelo1,
  4. MA Castro Vida1,
  5. EJ Alegre Del Rey2
  1. 1Hospital De Poniente, Pharmacy, Almeria, Spain
  2. 2Hospital Universitario Puerto Real, Pharmacy, Cadiz, Spain


Background and Importance Sacituzumab govitecan (SG) was recently approved by European Medicines Agency for heavily treated metastatic breast cancer (mBC) patients positive hormone receptor (HR+) and human epidermal growth factor receptor-2(HER2) negative supported by TROPiCS-02 trial which compare standard chemotherapy (ChT). Pivotal study results in overall survival (OS) was HR=0,78 IC95% (0,65–0,95). OS difference in median survival times was: 3,3 months. Although medians are commonly used in oncology to measure the magnitude of the benefit between different drugs, this is not accurate because only measures the difference in one point of the curves. A visual inspection of Kaplan-Meier’s survival functions of TROPiCS-02 suggested that the difference of medians could overestimate the OS benefit, as the curves separate in the central area.

Aim and Objectives The aim of study was to reanalyse the OS benefit of SG from pivotal clinical trial by calculating the difference in mean survival time by area-under curves (AUC)-based methods.

Material and Methods We use WebPoltDigitizer 4.6 to extract survival data at 100 points in each Kaplan-Meier’s OS curves. Mean survival times were estimated by AUC with Seruga’s method (Ann Oncol 2012). with or without a correction from Fenix’s method (Eur J Clin Pharm 2015). The later prevents underestimation by subtracting the areas corresponding to the proportion of the population whose survival is greater than the maximum observation time.

Results The AUC-estimated difference for SG vs. standard ChT were 2,30 by Seruga’s AUC method and 2,35 months with the correction from Fenix et al. It was 1 month less than the difference of medians showed the pivotal study.

Conclusion and Relevance European Society Medical Oncology rated this drug-indication with a score of 3 (not substantial benefit) in their Magnitude of Clinical Benefit Scale (0 to 5). Moreover, the difference of medians overestimated the benefit in the pivotal trial, as it was just shown by AUC-methods. These results suggest a modest benefit for SG in mBC HR+/HER2-. Indeed AUC-methods could be a good option when difference of medians are doubtful to estimate the benefit; its use should be extended.

References and/or Acknowledgements 1. Seruga B, Pond GR, Hertz PC. Comparison of absolute benefits of anticancer therapies determined by snapshot and area methods. Ann Oncol. 2012;23(11):2977–82.

Conflict of Interest No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.